PMVP logo

PMVP
PMV Pharmaceuticals Inc

478
Mkt Cap
$72.37M
Volume
94,986.00
52W High
$1.84
52W Low
$0.81
PE Ratio
-0.86
PMVP Fundamentals
Price
$1.32
Prev Close
$1.36
Open
$1.36
50D MA
$1.38
Beta
1.03
Avg. Volume
706,059.00
EPS (Annual)
-$1.14
P/B
0.60
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
BML Capital Management LLC Acquires 1,252,388 Shares of PMV Pharmaceuticals, Inc. $PMVP
BML Capital Management LLC increased its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 33.4% in the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
PMV Pharmaceuticals (NASDAQ:PMVP) Posts Quarterly Earnings Results, Hits Estimates
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40...
MarketBeat·6d ago
News Placeholder
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; PMV Pharma) today announced a partnership to develop Foundation Medicines tissue-based comprehensive genomic profiling test...
Business Wire·1y ago
News Placeholder
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2...
Globe Newswire·2y ago
News Placeholder
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation...
Globe Newswire·2y ago
News Placeholder
PEAK6 Investments LLC Invests $200,000 in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)
PEAK6 Investments LLC purchased a new position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP Free Report) during the third quarter, Holdings Channel.com reports. The fund purchased...
Zolmax·2y ago
News Placeholder
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. increased its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP Free Report) by 3.5% during the third quarter, according to the...
Zolmax·2y ago
News Placeholder
PMV Pharmaceuticals reports FY results
PMV Pharmaceuticals reports FY results...
SeekingAlpha.com: All News·2y ago
News Placeholder
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
Strategic Focus on Rezatapopt Advances as Company Extends Cash RunwayRelated Stocks: PMVP...
GuruFocus·2y ago
News Placeholder
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors...
Globe Newswire·2y ago

Latest PMVP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.